Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C

Antiviral Therapy

Volumn 20, Issue 1, 2015, Pages 65-72

  Labarga, Pablo ^a,b   Fernández Montero, José V ^a   De Mendoza, Carmen ^c   Barreiro, Pablo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Clinica La Luz   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; VIRUS ANTIGEN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ADULT; ALCOHOL ABUSE; ALLELE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IL28B GENE; LIVER DISEASE; LIVER FIBROSIS; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; VIRAL CLEARANCE; VIRUS RESISTANCE; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SURVIVAL; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COINFECTION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84927712679     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2827     Document Type: Article

References (21)

1. Mallet V, Gilgenkrantz H, Serpaggi J, et al. The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149:399-403.
2. Fernández-Montero JV, Barreiro P, Vispo E, et al. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy. Antivir Ther 2014; 19:287-292.
3. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677-684.
4. van der Meer AJ, Veldt B, Feld J, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-2593.
5. Soriano V, Maida I, Núñez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther 2004; 9:987-992.
6. Berenguer J, Alvarez-Pellicer J, Martín P, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus. Hepatology 2009; 50:407-413.
7. Macías J, Berenguer J, Japán MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with HIV/hepatitis C virus. Hepatology 2009; 50:1056-1063.
8. Konerman MA, Mehta S, Sutcliffe C, et al. Fibrosis progression in HIV/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014; 59:767-775.
9. Thomas DL. Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence. Top Antivir Med 2014; 21:152-156.
10. Shiffman ML, Benhamou Y. HCV F1/2 patients: treat now or continue to wait. Liver Int 2014; 34 Suppl 1:79-84.
11. Barreiro P, Fernández-Montero JV, de Mendoza C, Labarga P, Soriano V. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res 2014; 105:1-7.
12. Thompson MA, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Accessed 5 March 2014.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
14. European AIDS Clinical Society (EACS). Guidelines version 7.1 (October 2013). (Accessed 5 March 2014.) Available from www.europeanaidsclinicalsociety.org
15. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
16. Crowell TA, Gebo K, Balagopal A, Fleishman J, Agwu A, Berry S. Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV. J Acquir Immune Defic Syndr 2014; 65:429-437.
17. Linas BP, Wang B, Smurzynski M, et al. The impact of HIV/ HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat 2011; 18:506-512.
18. Castellares C, Barreiro P, Martín-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15:165-172.
19. Graham CS, Baden L, Yu E, et al. Influence of HIV infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
20. Limketkai BN, Mehta S, Sutcliffe C, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-378.
21. Berenguer J, Alvarez-Pellicer J, Carrero A, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with HIV and hepatitis C virus. J Hepatol 2013; 58:1104-1112.